FDA Approves Sunharbo (asundexian), the World’s First FXIa Inhibitor, to Reduce Stroke Risk in Adults with Recent Non‑Cardioembolic Ischemic Stroke or High‑Risk TIA

　　On November 9,2026,the U.S.Food and Drug Administration(FDA)approved Sunharbo(asundexian)50 mg tablets,the world’s first factor XIa(FXIa)inhibitor.This novel oral anticoagulant/antiplatelet agent acts on the intrinsic coagulation pathway and is indicated for use with antiplatelet therapy to reduce stroke risk in certain adult patients.

　　The drug is indicated for adults with a recent mild‑to‑moderate non‑cardioembolic ischemic stroke or high‑risk transient ischemic attack(TIA).Non‑cardioembolic ischemic stroke refers to stroke caused by non‑cardiac thrombi,excluding cardioembolic events such as those from atrial fibrillation.Treatment should be initiated within a defined time window after symptom onset,based on physician assessment,to lower the risk of recurrent stroke.

　　The efficacy of Sunharbo was established in the OCEANIC‑STROKE Phase III trial,a multicenter,randomized,double‑blind,placebo‑controlled study enrolling 12,327 adults with recent non‑cardioembolic ischemic stroke(NIH Stroke Scale score≤15)or high‑risk TIA.Patients were randomized within 72 hours of symptom onset to receive Sunharbo or placebo,with both groups receiving standard antiplatelet therapy.Results showed that once‑daily 50 mg Sunharbo reduced the risk of ischemic stroke by 26%compared with placebo.The median treatment duration was 14.2 months,demonstrating that adding an FXIa inhibitor to standard antiplatelet therapy further reduces stroke recurrence in this population.

　　Regarding safety,the overall incidence of major bleeding was similar between the Sunharbo and placebo groups.However,the risk of major bleeding was higher in patients aged 75 years or older and within the first 90 days of treatment,indicating a need for close monitoring for bleeding in these subgroups.The incidence of gastrointestinal bleeding was also higher with Sunharbo.The most common adverse reaction(incidence≥3%)was diarrhea.Patients should seek medical attention for signs of bleeding such as black stools,vomiting blood,excessive bruising,dizziness,or fatigue,as well as persistent diarrhea or dehydration.Blood counts and coagulation tests may be required.

　　Concomitant use of Sunharbo with P‑gp and strong CYP3A4 inducers(e.g.,carbamazepine)is not recommended,as these may reduce the drug’s efficacy.The drug is not recommended for patients with moderate or severe hepatic impairment.

　　For perioperative management,Sunharbo should be discontinued at least 24 hours before elective surgery or invasive procedures.After thrombolytic therapy for acute ischemic stroke,resumption should be delayed for at least 24 hours.Importantly,Sunharbo is not approved for stroke prevention in patients with atrial fibrillation,who require alternative anticoagulation regimens.

　　In summary,as the first‑in‑class FXIa inhibitor,Sunharbo offers a new option for reducing recurrent stroke risk in adults with recent non‑cardioembolic ischemic stroke or high‑risk TIA when added to antiplatelet therapy,with a 26%risk reduction demonstrated in Phase III trials.However,close monitoring for bleeding is required in older adults,early in treatment,and for gastrointestinal bleeding.Concomitant medications,hepatic function,and perioperative/thrombolysis‑related discontinuation must be strictly managed under medical guidance,and the drug is not indicated for atrial fibrillation‑related stroke prevention.